DrugBank Appoints Lisa Downey as CEO, Co-Founder Mike Wilson Moves to Chief Product Role

Oct 21, 2025
DrugBank has named Lisa Downey as its new CEO, with Co-Founder Mike Wilson transitioning to Chief Product Officer to focus on AI and data intelligence initiatives.

DrugBank has announced a leadership transition as it advances its AI-driven biomedical intelligence initiatives, according to a press release. Effective October 6, Lisa Downey has been appointed Chief Executive Officer, while Co-Founder Mike Wilson moves from CEO to Chief Product Officer.

Downey brings nearly two decades of experience in healthcare, life sciences, and data transformation, having previously held leadership roles at Clarivate and GlobalData. In her new role, she will oversee DrugBank’s next phase of AI-powered innovation and global growth.

As Chief Product Officer, Wilson will lead the development of DrugBank’s platform, expanding its use of machine learning and predictive modeling to enhance biomedical data accessibility for scientists and developers.

The leadership changes coincide with DrugBank’s upcoming twentieth anniversary in January, marking its evolution from a University of Alberta research project to a global biomedical intelligence platform serving clients across the pharmaceutical, biotech, academic, and healthcare sectors.

We hope you enjoyed this article

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Free newsletter

Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

Market report

2025 Generative AI in Professional Services Report

Thomson Reuters

This report by Thomson Reuters explores the integration and impact of generative AI technologies, such as ChatGPT and Microsoft Copilot, within the professional services sector. It highlights the growing adoption of GenAI tools across industries like legal, tax, accounting, and government, and discusses the challenges and opportunities these technologies present. The report also examines professionals' perceptions of GenAI and the need for strategic integration to maximize its value.

Read more
Free, six days a week

Daily AI Brief: the AI news that matters, in your inbox.